natco pharma semaglutide Will this court fight make the world's hottest weight-loss drug cheaper? | Health News NATCO Pharma Launches Generic Semaglutide

One published case report described a patient who developed paranoia and visual hallucinations while using compounded tirzepatide

Ozempic and Wegovy, both based on the active ingredient semaglutide, were primarily designed to improve blood sugar control in type 2 diabetes

Medicare Part D launched the GLP-1 Bridge program on July 1, 2026, covering Wegovy (injection and tablet), Zepbound (KwikPen only), and Foundayo for weight management at $50/month through December 31, 2027

Weight loss results vary by individual

Even after supply normalized, the genie proved hard to put back in the bottle

In metabolic care, complexity is a cost